ONCT News and Press, Oncternal Therapeutics Inc. From 06/02/22

Oncternal Therapeutics (NASDAQ:ONCT) granted options to buy 70K common shares to its new employee Ted Shih, who joined as head, Clinical Science. The award was made on June 1 under Oncternal's 2021 Employment Inducement Incentive Award Plan, and can be exercise at $1.56 per share, w...

Gainers: Helius Medical Technologies (HSDT) +57%. Tonix Pharmaceuticals  TNXP +49%. NeuroOne Medical Technologies (NMTC) +16%. Oncternal Therapeutics (ONCT) +16%. Butterfly Network (BFLY) +15%. Losers: Enochian Biosciences ENOB -37%. Icosavax ...

3 Hot Penny Stocks to Add to Your End of May Watchlist With another day of positive trading for penny stocks and blue chips, there is a lot of bullish sentiment to go around. While it is tough to say if this bullish momentum will continue into the near future, it is encouraging for thos...

Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to historical ORR of...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q1 2022 Earnings Call May 05, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q1 2022 Earnings Call Tran...

Oncternal Therapeutics, Inc (ONCT) Q1 2022 Earnings Conference Call May 5, 2022, 5:00 PM ET Company Participants James Breitmeyer – President & Chief Executive Officer Richard Vincent – Chief Financial Officer Salim Yazji – Chief Medical Officer Conference Call Partic...

Oncternal Therapeutics press release (NASDAQ:ONCT): Q1 GAAP EPS of -$0.20 beats by $0.04. Revenue of $0.7M (-6.7% Y/Y) beats by $0.17M. As of March 31, 2022, ONCT had ~49.4 million shares of common stock outstanding, $82.2 million in cash and cash equivalents and no debt. The company believe ...

Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022 Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial of zilovertamab in combination with ibrutinib for patients with MCL and CLL...

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial mar...

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...